Professor Stephen Mulligan

Adjunct Professor

G08 - Biochemistry and Microbiology Building
The University of Sydney


Research interests

Chronic Lymphocytic Leukaemia (CLL)

Current research students

Project title Research student
Hypoxic Microenvironment in Chronic Lymphocytic Leukemia and Novel Treatment Strategies Yandong SHEN

Keywords

Leukaemia; Proteomics; Haematology; Haematological malignancy; Immunology

Selected grants

2015

  • Australasian, phase II, multicentre, randomised study of efficacy and safety for dose reduced fludarabine, cyclophosphamide and intravenous (i.v.) obinutuzumab versus oral chlorambucil and i.v. obinutuzumab in previously untreated, comorbid, elderly (≥65; Mulligan S; The Leukaemia Foundation of Australia Limited/National Research Program.
  • Australasian, phase II, multicentre, randomised study of efficacy & safety for dose reduced fludarabine, cyclophosphamide & iv obinutuzumab vs oral chlorambucil & iv obinutuzumab in previously untreated, comorbid, elderly (≥65 yrs) patients with CLL; Mulligan S; DVC Research/Bridging Support Grant.

2012

  • Next generation sequencing of TP53, ATM and a panel of novel target genes in an elderly clinical trial CLL cohort - correlation with cytogenetics, FISH and clinical outcomes; Badoux , Badoux X, Mulligan S, Ward C; CLL (Chronic Lymphocytic Leukemia) Global Research Foundation/Research Support.

2011

  • Patterns of differentially abundant proteins on progressive chronic lymphocytic leukaemias; Christopherson R, Mulligan S; The Leukaemia Foundation of Australia Limited/Grants in Aid.

2008

  • Proteomic responses of B-lymphoproliferative disorders to fludarabine; Christopherson R, Mulligan S; The Leukaemia Foundation of Australia Limited/Grants in Aid.

2006

  • Global phenotype profiling of chronic lymphocytic leukemia; Mulligan S, Christopherson R; CLL (Chronic Lymphocytic Leukemia) Global Research Foundation/Project Grant.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Huang, P., Mactier, S., Best, O., Belov, L., Kaufman (nee Alexander), K., Pascovici, D., Mulligan, S., Christopherson, R. (2016). Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma, in press. [More Information]
  • Huang, P., Mactier, S., Armacki, N., Best, O., Belov, L., Kaufman (nee Alexander), K., Pascovici, D., Mulligan, S., Christopherson, R. (2016). Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma, 57(5), 1033-1043. [More Information]
  • Li, J., Best, O., Mulligan, S., Fernando, S. (2016). Serum from a subset of patients with chronic lymphocytic leukemia and large local reactions to mosquito bites induces upregulation of CD63 surface expression on basophils in atopic donors. Leukemia & Lymphoma, in press.
  • Hamad, N., Kliman, D., Best, G., Caramins, D., Hertzberg, M., Lindeman, R., Porter, R., Mulligan, S. (2015). Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: five cases, a literature review and discussion of management. British Journal of Haematology, 168(3), 350-360. [More Information]
  • Sandhu, S., Mulligan, S. (2015). Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia. Haematologica, 100(4), 411-414. [More Information]
  • Kaufman, K., Jenkins, Y., Alomari, M., Mirzaei, M., Best, O., Pascovici, D., Mactier, S., Mulligan, S., Haynes, P., Christopherson, R. (2015). The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia. Oncotarget, 6(38), 40981-40997. [More Information]
  • Crassini, K., Stevenson, W., Mulligan, S., Best, O. (2015). The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. Leukemia & Lymphoma, 56(12), 3407-3417. [More Information]
  • Huang, P., Best, O., Almazi, J., Belov, L., Davies, Z., Majid, A., Dyer, M., Pascovici, D., Mulligan, S., Christopherson, R. (2014). Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma, 55(9), 2085-2092. [More Information]
  • Mulligan, S., Karlsson, K., Strömberg, M., Jonsson, V., Gill, D., Hammerstrom, J., Hertzberg, M., McLennan, R., Uggla, B., Norman, J., et al (2014). Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia. Leukemia & Lymphoma, 55(12), 2769-2777. [More Information]
  • Christopherson, R., Mactier, S., Almazi, J., Kohnke, P., Best, O., Mulligan, S. (2014). Mechanisms of action of fludarabine nucleoside against human raji lymphoma cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 33(4-6), 375-383. [More Information]
  • Adena, M., Houltram, J., Mulligan, S., Todd, C., Malanos, G. (2014). Modelling the Cost Effectiveness of Rituximab in Chronic Lymphocytic Leukaemia in First-Line Therapy and Following Relapse. PharmacoEconomics, 32(2), 193-207. [More Information]
  • Hafner, J., Kumar, K., Mulligan, S., Ng, K. (2014). Multifocal central nervous system demyelination and Lhermitte's phenomenon secondary to combination chemotherapy for chronic lymphocytic leukaemia. Journal of the Neurological Sciences, 338(1-2), 218-219. [More Information]
  • Alomari, M., Mactier, S., Kaufman (nee Alexander), K., Best, O., Mulligan, S., Christopherson, R. (2014). Profiling the lipid raft proteome from human MEC1 chronic lymphocytic Leukemia Cells. Journal of Proteomics & Bioinformatics, S7, 005. [More Information]
  • Che, Y., Best, G., Zhong, L., Kaufman (nee Alexander), K., Mactier, S., Raftery, M., Graves, L., Mulligan, S., Christopherson, R. (2013). Hsp90 Inhibitor SNX-7081 Dysregulates Proteins Involved with DNA Repair and Replication and the Cell Cycle in Human Chronic Lymphocytic Leukemia (CLL) Cells. Journal of Proteome Research, 12(4), 1710-1722. [More Information]
  • Freeman, J., Crassini, K., Best, G., Forsyth, C., MacKinlay, N., Han, P., Stevenson, W., Mulligan, S. (2013). Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leukemia & Lymphoma, 54(1), 99-104. [More Information]
  • Huang, P., Kohnke, P., Belov, L., Best, G., Mulligan, S., Christopherson, R. (2013). Profiles of surface mosaics on chronic lymphocytic leukemias distinguish stable and progressive subtypes. Journal of Pharmacy and Pharmaceutical Sciences, 16(2), 231-237. [More Information]
  • Best, O., Crassini, K., Freeman, J., Mulligan, S. (2013). The clinical significance of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukaemia (CLL). Scandinavian Journal Of Infectious Diseases, 45(9), 729-729. [More Information]
  • Almazi, J., Mactier, S., Best, G., Crossett, B., Mulligan, S., Christopherson, R. (2012). Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53. Proteomics - Clinical Applications, 6(5-6), 279-290. [More Information]
  • Mulligan, S. (2012). Monoclonal B-lymphocytosis: reflections and definitions. Leukemia & Lymphoma, 53(9), 1647-1650. [More Information]
  • Huang, P., Best, G., Belov, L., Mulligan, S., Christopherson, R. (2012). Surface profiles for subclassification of chronic lymphocytic leukemia. Leukemia & Lymphoma, 53(6), 1046-1056. [More Information]
  • Best, G., Che, Y., Singh, N., Forsyth, C., Christopherson, R., Mulligan, S. (2012). The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leukemia & Lymphoma, 53(7), 1367-1375. [More Information]
  • Henrich, S., Mactier, S., Best, G., Mulligan, S., Crossett, B., Christopherson, R. (2011). Fludarabine Nucleoside Modulates Nuclear "Survival and Death" Proteins in Resistant Chronic Lymphocytic Leukemia Cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 30(12), 1181-1189. [More Information]
  • Cassano, C., Mactier, S., Mulligan, S., Belov, L., Huang, P., Christopherson, R. (2010). Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders. International Journal of Proteomics, 2010 (Article ID 964251), 964251-1-964251-9. [More Information]
  • Kohnke, P., Mulligan, S., Christopherson, R. (2009). Membrane proteomics for leukemia classification and drug target identification. Current Opinion in Molecular Therapeutics, 11(6), 603-610. [More Information]
  • Barber, N., Gez, S., Belov, L., Mulligan, S., Woolfson, A., Christopherson, R. (2009). Profiling CD antigens on leukaemias with an antibody microarray. FEBS Letters, 583(11), 1785-1791. [More Information]
  • Henrich, S., Mactier, S., Crossett, B., Mulligan, S., Christopherson, R. (2008). Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 27, 634-640. [More Information]
  • Mulligan, S. (2007). Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab - Double jeopardy. Leukemia and Lymphoma, 48(10), 1885-1887. [More Information]
  • Belov, L., Mulligan, S., Barber, N., Woolfson, A., Scott, M., Stoner, K., Chrisp, J., Sewell, W., Bradstock, K., Bendall, L., Sartor, M., Young, G., Wiley, J., Christopherson, R., et al (2006). Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. British Journal of Haematology, 135(2), 184-97. [More Information]
  • Christopherson, R., Stoner, K., Barber, N., Belov, L., Woolfson, A., Scott, M., Bendall, L., Mulligan, S. (2006). Classification of AML using a monoclonal antibody microarray. Methods in molecular medicine, 125, 241-251. [More Information]
  • Belov, L., Huang, P., Chrisp, J., Mulligan, S., Christopherson, R. (2005). Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. Journal of Immunological Methods, 305(1), 10-19. [More Information]
  • Wilson, P., Mulligan, S., Christopherson, R. (2004). Metabolic Response Patterns Of Nucleotides In B-Cell Chronic Lymphocytic Leukaemias To Cladribine, Fludarabine And Deoxycoformycin. Leukemia Research: clinical and laboratory studies, 28(7), 725-731.
  • Belov, L., Huang, P., Barber, N., Mulligan, S., Christopherson, R. (2003). Identification of repertoires of surface antigens on leukemias using an antibody mircroarray. Proteomics, 3(11), 2147-2154. [More Information]

2016

  • Huang, P., Mactier, S., Best, O., Belov, L., Kaufman (nee Alexander), K., Pascovici, D., Mulligan, S., Christopherson, R. (2016). Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma, in press. [More Information]
  • Huang, P., Mactier, S., Armacki, N., Best, O., Belov, L., Kaufman (nee Alexander), K., Pascovici, D., Mulligan, S., Christopherson, R. (2016). Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma, 57(5), 1033-1043. [More Information]
  • Li, J., Best, O., Mulligan, S., Fernando, S. (2016). Serum from a subset of patients with chronic lymphocytic leukemia and large local reactions to mosquito bites induces upregulation of CD63 surface expression on basophils in atopic donors. Leukemia & Lymphoma, in press.

2015

  • Hamad, N., Kliman, D., Best, G., Caramins, D., Hertzberg, M., Lindeman, R., Porter, R., Mulligan, S. (2015). Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: five cases, a literature review and discussion of management. British Journal of Haematology, 168(3), 350-360. [More Information]
  • Sandhu, S., Mulligan, S. (2015). Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia. Haematologica, 100(4), 411-414. [More Information]
  • Kaufman, K., Jenkins, Y., Alomari, M., Mirzaei, M., Best, O., Pascovici, D., Mactier, S., Mulligan, S., Haynes, P., Christopherson, R. (2015). The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia. Oncotarget, 6(38), 40981-40997. [More Information]
  • Crassini, K., Stevenson, W., Mulligan, S., Best, O. (2015). The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. Leukemia & Lymphoma, 56(12), 3407-3417. [More Information]

2014

  • Huang, P., Best, O., Almazi, J., Belov, L., Davies, Z., Majid, A., Dyer, M., Pascovici, D., Mulligan, S., Christopherson, R. (2014). Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma, 55(9), 2085-2092. [More Information]
  • Mulligan, S., Karlsson, K., Strömberg, M., Jonsson, V., Gill, D., Hammerstrom, J., Hertzberg, M., McLennan, R., Uggla, B., Norman, J., et al (2014). Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia. Leukemia & Lymphoma, 55(12), 2769-2777. [More Information]
  • Christopherson, R., Mactier, S., Almazi, J., Kohnke, P., Best, O., Mulligan, S. (2014). Mechanisms of action of fludarabine nucleoside against human raji lymphoma cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 33(4-6), 375-383. [More Information]
  • Adena, M., Houltram, J., Mulligan, S., Todd, C., Malanos, G. (2014). Modelling the Cost Effectiveness of Rituximab in Chronic Lymphocytic Leukaemia in First-Line Therapy and Following Relapse. PharmacoEconomics, 32(2), 193-207. [More Information]
  • Hafner, J., Kumar, K., Mulligan, S., Ng, K. (2014). Multifocal central nervous system demyelination and Lhermitte's phenomenon secondary to combination chemotherapy for chronic lymphocytic leukaemia. Journal of the Neurological Sciences, 338(1-2), 218-219. [More Information]
  • Alomari, M., Mactier, S., Kaufman (nee Alexander), K., Best, O., Mulligan, S., Christopherson, R. (2014). Profiling the lipid raft proteome from human MEC1 chronic lymphocytic Leukemia Cells. Journal of Proteomics & Bioinformatics, S7, 005. [More Information]

2013

  • Che, Y., Best, G., Zhong, L., Kaufman (nee Alexander), K., Mactier, S., Raftery, M., Graves, L., Mulligan, S., Christopherson, R. (2013). Hsp90 Inhibitor SNX-7081 Dysregulates Proteins Involved with DNA Repair and Replication and the Cell Cycle in Human Chronic Lymphocytic Leukemia (CLL) Cells. Journal of Proteome Research, 12(4), 1710-1722. [More Information]
  • Freeman, J., Crassini, K., Best, G., Forsyth, C., MacKinlay, N., Han, P., Stevenson, W., Mulligan, S. (2013). Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leukemia & Lymphoma, 54(1), 99-104. [More Information]
  • Huang, P., Kohnke, P., Belov, L., Best, G., Mulligan, S., Christopherson, R. (2013). Profiles of surface mosaics on chronic lymphocytic leukemias distinguish stable and progressive subtypes. Journal of Pharmacy and Pharmaceutical Sciences, 16(2), 231-237. [More Information]
  • Best, O., Crassini, K., Freeman, J., Mulligan, S. (2013). The clinical significance of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukaemia (CLL). Scandinavian Journal Of Infectious Diseases, 45(9), 729-729. [More Information]

2012

  • Almazi, J., Mactier, S., Best, G., Crossett, B., Mulligan, S., Christopherson, R. (2012). Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53. Proteomics - Clinical Applications, 6(5-6), 279-290. [More Information]
  • Mulligan, S. (2012). Monoclonal B-lymphocytosis: reflections and definitions. Leukemia & Lymphoma, 53(9), 1647-1650. [More Information]
  • Huang, P., Best, G., Belov, L., Mulligan, S., Christopherson, R. (2012). Surface profiles for subclassification of chronic lymphocytic leukemia. Leukemia & Lymphoma, 53(6), 1046-1056. [More Information]
  • Best, G., Che, Y., Singh, N., Forsyth, C., Christopherson, R., Mulligan, S. (2012). The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leukemia & Lymphoma, 53(7), 1367-1375. [More Information]

2011

  • Henrich, S., Mactier, S., Best, G., Mulligan, S., Crossett, B., Christopherson, R. (2011). Fludarabine Nucleoside Modulates Nuclear "Survival and Death" Proteins in Resistant Chronic Lymphocytic Leukemia Cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 30(12), 1181-1189. [More Information]

2010

  • Cassano, C., Mactier, S., Mulligan, S., Belov, L., Huang, P., Christopherson, R. (2010). Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders. International Journal of Proteomics, 2010 (Article ID 964251), 964251-1-964251-9. [More Information]

2009

  • Kohnke, P., Mulligan, S., Christopherson, R. (2009). Membrane proteomics for leukemia classification and drug target identification. Current Opinion in Molecular Therapeutics, 11(6), 603-610. [More Information]
  • Barber, N., Gez, S., Belov, L., Mulligan, S., Woolfson, A., Christopherson, R. (2009). Profiling CD antigens on leukaemias with an antibody microarray. FEBS Letters, 583(11), 1785-1791. [More Information]

2008

  • Henrich, S., Mactier, S., Crossett, B., Mulligan, S., Christopherson, R. (2008). Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 27, 634-640. [More Information]

2007

  • Mulligan, S. (2007). Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab - Double jeopardy. Leukemia and Lymphoma, 48(10), 1885-1887. [More Information]

2006

  • Belov, L., Mulligan, S., Barber, N., Woolfson, A., Scott, M., Stoner, K., Chrisp, J., Sewell, W., Bradstock, K., Bendall, L., Sartor, M., Young, G., Wiley, J., Christopherson, R., et al (2006). Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. British Journal of Haematology, 135(2), 184-97. [More Information]
  • Christopherson, R., Stoner, K., Barber, N., Belov, L., Woolfson, A., Scott, M., Bendall, L., Mulligan, S. (2006). Classification of AML using a monoclonal antibody microarray. Methods in molecular medicine, 125, 241-251. [More Information]

2005

  • Belov, L., Huang, P., Chrisp, J., Mulligan, S., Christopherson, R. (2005). Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. Journal of Immunological Methods, 305(1), 10-19. [More Information]

2004

  • Wilson, P., Mulligan, S., Christopherson, R. (2004). Metabolic Response Patterns Of Nucleotides In B-Cell Chronic Lymphocytic Leukaemias To Cladribine, Fludarabine And Deoxycoformycin. Leukemia Research: clinical and laboratory studies, 28(7), 725-731.

2003

  • Belov, L., Huang, P., Barber, N., Mulligan, S., Christopherson, R. (2003). Identification of repertoires of surface antigens on leukemias using an antibody mircroarray. Proteomics, 3(11), 2147-2154. [More Information]

To update your profile click here. For support on your academic profile contact .